| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
|
Medicine details |
|
| Medicine name | cobimetinib (Cotellic®) |
| Formulation | 20 mg film-coated tablet |
| Reference number | 2119 |
| Indication | In combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600 mutation |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/11/2015 |
| NICE guidance | |